- Home
- GILD vs META Comparison
GILD vs META Comparison
Compare GILD & META Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | META |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 1.5T |
| IPO Year | 2003 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GILD | META |
|---|---|---|
| Price | $125.74 | $560.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 40 |
| Target Price | $148.39 | ★ $838.63 |
| AVG Volume (30 Days) | 7.6M | ★ 15.5M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.55% | 0.31% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | 1.61 | ★ 10.44 |
| Revenue | $24,689,000,000.00 | ★ $40,653,000,000.00 |
| Revenue This Year | $4.68 | $26.99 |
| Revenue Next Year | $6.04 | $18.21 |
| P/E Ratio | $77.67 | ★ $53.85 |
| Revenue Growth | 9.98 | ★ 47.09 |
| 52 Week Low | $107.75 | $520.26 |
| 52 Week High | $157.29 | $796.25 |
Technical Indicators
Market Signals| Indicator | GILD | META |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 37.76 |
| Support Level | $116.55 | $557.01 |
| Resistance Level | $126.46 | $615.40 |
| Average True Range (ATR) | 3.48 | 18.86 |
| MACD | 0.06 | -2.41 |
| Stochastic Oscillator | 40.31 | 2.11 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About META Meta Platforms Inc.
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.